

ReNerve

ASX:RNV

Transforming Nerve Repair Through Science

ReNerve Annual General Meeting presentation |
November 2025



ersonal use only

Important Notice & Disclaimer

Nature of Document: This presentation has been prepared and issued by ReNerve Ltd (Company) to provide general information about the Company. The information in this document is in summary form and should not be relied upon as a complete and accurate representation of any matters that a reader should consider in evaluating the Company. While management has taken every effort to ensure the accuracy of the material in this presentation, the Company have not verified the accuracy or completeness of the material contained in this presentation.

Not an offer: this presentation should not be distributed, transmitted, or viewed by any person in any jurisdiction where the distribution, transmission or viewing of this document would be unlawful under the securities or other laws of that or any other jurisdiction.

Not financial product advice: You should not act and should refrain from acting in reliance on this presentation. Nothing contained in this presentation constitutes investment, legal, tax or other advice. This presentation does not take into account the individual investment objectives, financial situation and particular needs of potential investors. Before making a decision to invest in the Company at any time, you should conduct, with the assistance of your broker or other financial or professional adviser, your own investigation in light of your particular investment needs, objectives and financial circumstances and perform your own analysis of the Company before making any investment decision.

Forward looking statements: This presentation contains forward-looking information about the Company and its operations. In certain cases, forward-looking information may be identified by such terms as "anticipates", "believes", "should", "could", "estimates", "target", "likely", "plan", "expects", "may", "intend", "shall", "will", or "would". These statements are based on information currently available to the Company and the Company provides no assurance that actual results will meet management's expectations. Forward-looking statements are subject to risk factors associated with the Company's business, many of which are beyond the control of the Company. It is believed that the expectations reflected in these statements are reasonable but they may be affected by a variety of variables and changes in underlying assumptions which could cause actual results or trends to differ materially from those expressed or implied in such statements. There can be no assurance that actual outcomes will not differ materially from these statements.

Disclaimer: No representation or warranty, express or implied, is made by the Company that the material contained in this presentation will be achieved or proved correct. Except for statutory liability which cannot be excluded, the Company, its directors, officers, and employees expressly disclaim any responsibility for the accuracy, fairness, sufficiency or completeness of the material contained in this presentation and excludes all liability whatsoever (including in negligence) for any loss or damage which may be suffered by any person as a consequence of any information in this presentation or any effort or omission therefrom. The Company will not update or keep current the information contained in this presentation or to correct any inaccuracy or omission which may become apparent, or to furnish any person with any further information. Any opinions expressed in the presentation are subject to change without notice. Anyone who wants to acquire Shares pursuant to the offer will need to complete the application form that accompanies the prospectus. A person should consider and rely only on the prospectus in deciding whether to invest. A copy of the prospectus is available by contacting the Company or by downloading from the Company's website (www.renerve.com.au).

Speculative nature of investment: Any potential investor should be aware that subscribing for Shares involves various risks. The Shares to be issued pursuant to the Prospectus lodged with ASIC by ReNerve Ltd carry no guarantee with respect to the payment of dividends, returns of capital or the market value of those Shares. An investment in Shares of the Company should therefore be considered very speculative.

ReNerve Ltd ABN 23 614 848 216

Executive Summary



Development of Novel Nerve Repair & Regeneration Products

ReNerve is developing a comprehensive portfolio of products for the nerve repair and regeneration markets and related surgical procedures, with clearly defined commercial position and demand.



Expanding Product Portfolio

3 product ranges in the US market with more coming



Strong Sales & Distribution Presence

ReNerve has established logistics, warehouse and invoicing infrastructure with a strong focus on building a sales distribution network for all products in the US.




Global Expansion & Commercialisation

Successful ongoing expansion within the first year of ASX listing into Ex-US markets in Asia, India, The Middle East, and The Americas.



Clinical & Professional Validation

Improved patient outcomes for post-surgical measures of pain and surgery satisfaction, as well as proven ease of use for surgeons.



ersonal use only

Activities for the past 12 months

Expanding our commercialisation presence

Completed an ASX IPO

Multiple regional partners

- Middle East, Mexico, India, Hong Kong

Partnership with Berkeley Biologics

- Brings Empliq brand of products
- Adds 4 product lines to the ReNerve sales portfolio
- Helps accelerate company sales
- Complementary to existing product portfolio

Added direct salespeople in the US

- 21 US distribution partners
- Ongoing hospital approvals and surgeon engagement

Positive NervAlign Nerve Cuff clinical study

- Expanded into a more comprehensive study

Company revenue rose 53% year on year



Company Portfolio




ersonal use only

Target Market

The Global Nerve Repair Biomaterials Market is projected to grow at a compound annual growth rate (CAGR) of 17.8% from 2024 to 2031 to USD\$6.19Bn.

Our Target Markets

- Global Nerve Repair Biomaterial Market
- Dermal and Amniotic Tissue Surgical Applications (Trauma, plastic surgery)
- Dermal and Amniotic Tissue Orthopaedics



ReNerve's Nerve Opportunity

ReNerve Nerve Cuff



ReNerve Nerve Conduit



ReNerve Nerve Guide Matrix



ReNerve Bionic Nerve




Product	<ul style="list-style-type: none"> Used on damaged or transected nerves with no gaps or gap closure 	<ul style="list-style-type: none"> Improved Nerve Cuff developed from scCO2 tissue, offering better product profile 	<ul style="list-style-type: none"> An 'off-the-shelf', ready to use nerve graft replacement with internal guidance infrastructure 	<ul style="list-style-type: none"> An 'off-the-shelf', continuous nerve replacement, in a ready to use nerve structure
Procedure Use	<ul style="list-style-type: none"> End to end suturing covered with a wrap/cuff Protective cuff for grafts 	<ul style="list-style-type: none"> Protecting injured nerve repairs 	<ul style="list-style-type: none"> Replaces damaged nerve section instead of using donor or harvested tissue 	<ul style="list-style-type: none"> The Bionic Nerve is a nerve guide matrix with ionic polymers designed to replace injured and damaged nerves for lengths from 1cm to 20cm
Application	<ul style="list-style-type: none"> Trauma Breast reconstruction Orthopaedics Oral & maxillofacial surgery 	<ul style="list-style-type: none"> Trauma Breast reconstruction Orthopaedics Foot and ankle 	<ul style="list-style-type: none"> Trauma Breast reconstruction Orthopaedics Hand & wrist 	<ul style="list-style-type: none"> Trauma Craniotomy Spinal cord injury Spinal cord surgery
Benefit	<ul style="list-style-type: none"> Bio-absorbed removing need for additional surgery Pliable and conforms 	<ul style="list-style-type: none"> Improved product profile to Nerve Cuff Stronger patient reimbursement 	<ul style="list-style-type: none"> Can be cut to ideal length Off-the-shelf, reducing logistics issues Simple to use and cost effective 	<ul style="list-style-type: none"> Enable production of nerves of bespoke dimension
FDA Status	Approved	Targeting market release 1H '26	Targeting CY27 filing	Targeting CY28 filing
TAM (USD)				


ersonal use only

Global Nerve Repair Biomaterial Market

Global Nerve Repair Biomaterial Market



Global Market by Segment



USD\$1.69Bn

The Global Nerve Repair Biomaterials Market was valued at USD\$1.69Bn in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 17.8% from 2024 to 2031 to USD\$6.19Bn.*



~900k

Nerve surgeries occur in the United States (US) per annum, with no more than 24% of nerve surgeries restoring to 'as good as it was'.



Nerve Compression

Approximately 1-in-4 nerve repair cases receive surgery repair, with 30% failure/revision rates.

* Global Nerve Repair Biomaterials Market Research Report (2020 – 2031)

Distribution Network



US Market Expanded Distribution Channels



Robust portfolio

- Expanded to 21 distributors across the US
- Full logistics, warehousing and invoicing in place
- Distributors can sell the entire ReNerve product range
- Will add additional to the network as products come to market

Focus surgical areas Subspecialties

- Hand (upper extremity)
- Breast
- Lower Extremity (M.D. & DPM)
- Plastics Reconstruction
- Head & Neck
- Spine

Ex-US Sales & Marketing

Sales Highlights



Final stages of approval process in India



Seeking multiple approval applications across Asia



Will use the US data and "Align" study for European approval submission



Looking to support the US sales growth

ReNerve Distribution



India

Significant potential due to population and open market. Have partnered with NetCentrix for approval and sales and marketing

Asia

On market in Hong Kong and Thailand, moving to strategic partners across the region

MIDDLE EAST

Entered into exclusive partnership with Union Mediscience B.S.C in the Middle East.

Strategy

Leveraging US approval and patient data for entry into global markets

- Targeting meaningful markets such as India and Asia
- Leveraging off FDA clearance and US patient data for Europe
- More approvals due in the next 12 months

ReNerve

NervAlign[®]

Nerve Cuff



ersonal use only

Key Features

Product

- Protects nerves during recovery post peripheral nerve repair
- Great handling characteristics and absorbed within 6 months

Patient Benefit

- Bio-absorbed within 6-months.
- Produced using a non-toxic method.
- Terminally sterilised with no residual chemicals.
- Covered under procedural reimbursement rather than individual product reimbursement.
- Promotes revascularisation and remodelling
- Semi-translucent

Surgeon Benefit

- Requires no change to surgical technique or procedures.
- Available in various sizes with ability to be trimmed to required shape.
- Is pliable and conforms, semi-translucent and easy to use

Cuff



ReNerve's "Align" Clinical Study

Patient Results

- Definitive clinical study on using NervAlign Nerve Cuff for nerve repair
- 120 patients per cohort
- Comparing standard of care vs treatment with NervAlign Nerve Cuff

Clinical Use

- Hundreds of patients implanted to date
- Received positive feedback from surgeons stating it handles well, is pliable and conforms and has resulted in strong patient outcomes.
- Positive surgeon feedback when used with attachment methods including sutures, glue, micro clips and 'nothing'.

The "Align" Study

Undertaking a definitive study in nerve repair following surgical neurolysis to show the benefit of protecting the nerve post nerve repair surgery.

Study Design: Two patient cohorts

- Control Group: Standard neurectomy repair
- Test Group: Neurectomy repair with NervAlign™ Nerve Cuff
- Based on the study which showed clear benefit for using the NervAlign™ Nerve Cuff


Key Outcomes:

- Testing for significance in Pain Reduction:
 - Secondary outcomes in patient recovery
 - Product performance in surgery
- Patient follow up around 6 to 9 months

Data presentation

- Aiming to complete recruitment by mid 2026
- Data accumulated along the way
- First 50 patients recruited to date
- Data likely to be published and presented in late 2026/early 2027

Comparison of Patient Pre & Post Surgery Pain Score



The comparison of pain scores between the two cohorts of patients

ReNerve



Empliq™

Product Range



Empliq Product Portfolio



	Empliq AmnioLite	Empliq AmnioDuo	Empliq Placental	Empliq Dermal
Description	Single-layer amniotic membrane allograft	Double-layer amniotic membrane allograft	Placental allograft including amniotic membrane and chorion	Deep-layer dermal matrix
Clinical Value	Natural barrier to protect wounds from external environment	Thicker barrier for complex wounds Improved handling characteristics	Natural barrier to protect wounds from external environment Additional structural support	Natural scaffold for protection, reinforcement and capillary formation No basement membrane - rapid tissue ingrowth and healing
Potential Applications	DFUs, VLUs, surgical wounds, vulnerable tissue	DFUs, VLUs, pressure injury, surgical wounds		Breast reconstruction, Tendon augmentation, abdominal wall repair, hernia repair


DFU = Diabetic foot ulcer; VLU = Venous leg ulcer

Personal use only

ReNerve

Product Development Pipeline

ersonal use only



Product Development Pipeline


Nerve conduit range

- Nerve Conduit and protector ranges
 - Includes the Nerve cap
 - Entering commercial validation batches
 - 3 types of conduits to come to market



Nerve guide matrix

- In the commercial development phase
- FDA approval pathway confirmed
- Next step GMP, commercial



Value drivers for the next 12 months

*Driving sales and
new products into
market*

2026 about major
commercial progress



Empliq products ranges now in the US market

- 4th product coming to market
- Complements the nerve cuff
- Faster sales growth through multiple products
- Ongoing hospital approvals and surgeon engagement

Continue to expand into Ex-US markets

- Establishing partners Ex-USA
- Pending approval in several countries in 2026
- Will leverage all clinical data and cases to expand globally
- Follow the same path for new products

Working with distributors for additional approvals

- Building our network of US distributors
- 2026 is about gaining more customer approvals

Ongoing Clinical Study

- Strong, positive data in 2025
- Ability to definitive clinical study
- The "Align" study underway and actively recruiting
- Initial data due in 2026

Company Milestones

2025

Partnership Signed for Mexico Market

R&D Tax Incentive Refund Received

Thailand Approval & First Hong Kong Sale

Positive Nerve Cuff Clinical Study Results Presented

Partnership for Indian Market Announced

Empliq launched in the US

Empliq initial sales

Next 6 months

NervAlign® Nerve Conduit into Market

Growing the Empliq brand

Initial Clinical Cases for the Nerve Conduit

Starting GMP manufacturing (Stage 3) runs of the Nerve Guide Matrix

NervAlign® Nerve Cuff approval in India

NervAlign® Nerve Cuff approval in Taiwan

NervAlign® Nerve Cuff Approvals in New Countries & Territories

Near Term

Nerve Guide Matrix GMP production

ReNerve 'Align' Study data

First clinical cases using the nerve guide matrix

Expansion of the Nerve Repair product portfolio

Continued sales growth


NervAlign® Nerve Cuff filing for European approval

Investment Highlights



In Market Products

Nerve Cuff transitioned from R&D to commercial sales with 3 product lines in market and nerve conduits coming.



Immediate Market Need

Products promote nerve injury recovery and wound repair leading to faster patient recovery and better outcomes.



Growing Market

Nerve repair biomaterials and related markets are forecast to grow by >17% pa, estimated to be worth **>US\$6.19Bn by 2031.**
USD\$1Bn+ market for human tissue product ranges



Diverse Product Portfolio

Building a complete product range in market with 3 in market and more coming in 2026. Additional products currently under development.



Growing Distribution

Continuing to build sales representation with a targeted-direct sales approach. Expanding globally.



Board & Management

Highly accomplished executive team with a proven track record in the development & commercialisation of medical opportunities.

ReNerve

ASX:RNV

Contact

ReNerve Limited

 +61 (03) 9482 3940

 info@renerve.com.au

 Level 10/99 Queen St, Melbourne, Victoria 3000 Australia



ersonal use only